Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Vlaar · SciRah

Researcher profile · Semantic Scholar

A. Vlaar

Share profile

A. Vlaar — researcher profile on SciRah

h-index: 17
Works: 56
Citations: 2,250

Most-cited papers

Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study
B. Schurink, E. Roos, Teodora Radonic, Ellis Barbé +26 more
2020The Lancet Microbe443 citations Open access
Semantic Scholar
The pathophysiology of sepsis and precision-medicine-based immunotherapy
E. Giamarellos-Bourboulis, A. Aschenbrenner, Michael Bauer, Christoph Bock +13 more
2024Nature Immunology351 citations Open access
Semantic Scholar
A guide to immunotherapy for COVID-19
F. L. van de Veerdonk, E. Giamarellos-Bourboulis, P. Pickkers, L. Derde +11 more
2022Nature Medicine284 citations Open access
Semantic Scholar
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
A. Vlaar, S. de Bruin, M. Busch, S. Timmermans +22 more
2020The Lancet Rheumatology151 citations Open access
Semantic Scholar
Uncovering heterogeneity in sepsis: a comparative analysis of subphenotypes
R. V. van Amstel, J. Kennedy, B. Scicluna, Lieuwe D. J. Bos +30 more
2023Intensive Care Medicine121 citations Open access
Semantic Scholar
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
A. Vlaar, M. Witzenrath, P. van Paassen, L. Heunks +21 more
2022The Lancet Respiratory Medicine119 citations Open access
Semantic Scholar
Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial.
E. Giamarellos-Bourboulis, A. Kotsaki, I. Kotsamidi, Aikaterini Efthymiou +50 more
2025Journal of the American Medical Association (JAMA)113 citations Open access
Semantic Scholar
Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts
Lieuwe D. J. Bos, M. Sjoding, P. Sinha, S. Bhavani +100 more
2021The Lancet Respiratory Medicine109 citations Open access
Semantic Scholar
Clinical features and prognostic factors in Covid-19: A prospective cohort study
S. de Bruin, Lieuwe D. J. Bos, M. V. van Roon, A. T. Tuip-de Boer +12 more
2021EBioMedicine94 citations Open access
Semantic Scholar
The immunology of sepsis: translating new insights into clinical practice
M. Kox, Michael Bauer, Lieuwe D. J. Bos, H. Bouma +20 more
2025Nature Reviews Nephrology66 citations Open access
Semantic Scholar
Complement activation in COVID-19 and targeted therapeutic options: A scoping review
E. H. T. Lim, Rombout B. E. van Amstel, Vieve Victoria de Boer, L. V. van Vught +4 more
2022Blood reviews56 citations Open access
Semantic Scholar
ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol
A. Kotsaki, P. Pickkers, M. Bauer, T. Calandra +16 more
2022BMJ Open56 citations Open access
Semantic Scholar
Lung Microbiota of Critically Ill Patients with COVID-19 Are Associated with Nonresolving Acute Respiratory Distress Syndrome
R. F. J. Kullberg, J. de Brabander, L. Boers, Jason J. Biemond +8 more
2022American Journal of Respiratory and Critical Care Medicine43 citations Open access
Semantic Scholar
Prolonged indoleamine 2,3-dioxygenase-2 activity and associated cellular stress in post-acute sequelae of SARS-CoV-2 infection
Li-Hui Guo, B. Appelman, Kirsten A. Mooij-Kalverda, R. Houtkooper +92 more
2023EBioMedicine37 citations Open access
Semantic Scholar
Indoleamine 2,3-dioxygenase (IDO)-1 and IDO-2 activity and severe course of COVID-19
Li-Hui Guo, B. Schurink, E. Roos, E. Nossent +44 more
2021Journal of Pathology37 citations Open access
Semantic Scholar
Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia
Quentin Philippot, A. Fekkar, A. Gervais, T. Le Voyer +61 more
2023Journal of Clinical Immunology29 citations Open access
Semantic Scholar
Persistent alveolar inflammatory response in critically ill patients with COVID-19 is associated with mortality
J. de Brabander, L. Boers, R. F. J. Kullberg, Shiqi Zhang +8 more
2023Thorax28 citations Open access
Semantic Scholar
Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trial
E. H. T. Lim, A. Vlaar, L. Bos, L. V. van Vught +78 more
2022Respiratory Research16 citations Open access
Semantic Scholar
Personalised immunotherapy in sepsis: a scoping review protocol
M. A. Slim, N. van Mourik, J. Dionne, S. Oczkowski +8 more
2022BMJ Open12 citations Open access
Semantic Scholar
Real-world Evidence of the Effects of Novel Treatments for COVID-19 on Mortality: A Nationwide Comparative Cohort Study of Hospitalized Patients in the First, Second, Third, and Fourth Waves in the Netherlands
M. A. Slim, B. Appelman, H. Peters-Sengers, D. Dongelmans +7 more
2022Open Forum Infectious Diseases11 citations Open access
Semantic Scholar
Association between dexamethasone treatment and the host response in COVID-19 patients admitted to the general ward
J. de Brabander, Erik H. A. Michels, Christine C. A. van Linge, O. Chouchane +80 more
2022Respiratory Research11 citations Open access
Semantic Scholar
Complement inhibition in severe COVID-19 – Blocking C5a seems to be key
E. H. T. Lim, A. Vlaar, S. de Bruin, M. Brouwer +1 more
2021EClinicalMedicine11 citations Open access
Semantic Scholar
Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients
E. Lim, A. Vlaar, S. de Bruin, S. Rückinger +83 more
2023Intensive Care Medicine Experimental9 citations Open access
Semantic Scholar
The alveolar fibroproliferative response in moderate to severe COVID-19-related acute respiratory distress syndrome and one-year follow up.
Shi-Qi Zhang, L. Boers, J. de Brabander, Laura B. van den Heuvel +12 more
2023American Journal of Physiology - Lung cellular and Molecular Physiology8 citations Open access
Semantic Scholar
Heterogeneity of treatment effect of vilobelimab in COVID-19: a secondary analysis of a randomised controlled trial
R. V. van Amstel, M. A. Slim, E. Lim, S. Rückinger +83 more
2024Critical Care7 citations Open access
Semantic Scholar
42nd International Symposium on Intensive Care & Emergency Medicine
E. Lim, D. van de Beek, S. de Bruin, S. Rückinger +6 more
2023Critical Care5 citations Open access
Semantic Scholar
Sex steroid hormones are associated with mortality in COVID-19 patients
Ingeborg E. van Zeggeren, A. Boelen, D. van de Beek, A. Heijboer +2 more
2021Medicine5 citations Open access
Semantic Scholar
Cyclophosphamide for interstitial lung disease-associated acute respiratory failure: mortality, clinical response and radiological characteristics
J. V. van Gemert, I. V. D. van den Berk, E. Nossent, L. Heunks +3 more
2021BMC Pulmonary Medicine5 citations Open access
Semantic Scholar
Anti-C5a Antibody (IFX-1) Treatment of Severe COVID-19: An Exploratory Phase 2 Randomized Controlled Trial
A. Vlaar, S. de Bruin, M. Busch, S. Timmermans +22 more
20205 citations Open access
Semantic Scholar
The effect of immunosuppressive therapies on the endothelial host response in critically ill COVID-19 patients
M. A. Slim, E. H. T. Lim, L. V. van Vught, A. T. Tuip-de Boer +8 more
2024Scientific Reports4 citations Open access
Semantic Scholar
Endothelial Permeability and the Angiopoietin/Tie2 System Following Mild and Severe COVID-19
Carolien Volleman, Roselique Ibelings, A. Vlaar, C. E. van den Brom +82 more
2023Artery Research4 citations Open access
Semantic Scholar
Absence of COVID-19 associated mucormycosis in a tertiary intensive care unit in the Netherlands
J. Schippers, P. Verweij, L. Heunks, K. V. van Dijk +21 more
2023Scientific Reports3 citations Open access
Semantic Scholar
85. Improved Survival with Dual Immunomodulator Treatment of ARDS by blocking C5a and IL-6 Activity: Subanalysis from the PANAMO Study in Critically Ill COVID-19 Patients
R. F. Chemaly, A. Vlaar, E.H.T. Lim, B. Burnett +7 more
2025Open Forum Infectious Diseases2 citations Open access
Semantic Scholar
A phase I trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenously administered low-anticoagulant heparin (M6229) in critically ill sepsis patients
N. van Mourik, Rombout B. E. van Amstel, M. A. Slim, L. V. van Vught +11 more
2025Intensive Care Medicine Experimental2 citations Open access
Semantic Scholar
Vilobelimab in Combination With Tocilizumab or Baricitinib Dramatically Improves Mortality in Critically Ill COVID-19 Patients: A Subgroup Analysis
A. F. Shorr, A. Vlaar, E. Lim, B. Burnett +7 more
2024C40. ARDS AND ACUTE RESPIRATORY FAILURE: MECHANISM, RISK, AND OUTCOMES2 citations
Semantic Scholar
VILOBELIMAB IN COMBINATION WITH TOCILIZUMAB MAY SYNERGISTICALLY IMPROVE MORTALITY IN CRITICALLY ILL COVID-19 PATIENTS: A POST-HOC ANALYSIS OF THE PHASE III PANAMO STUDY
C. Sandrock, A. Vlaar, E.H.T. Lim, B. Burnett +7 more
2024Chest2 citations
Semantic Scholar
Anti-C5a Vilobelimab Reduces All-cause Mortality in Critically Ill COVID-19 Patients and in Those With Severe ARDS: A Phase 3 Randomized Double-blind, Placebo-controlled Study
M. Witzenrath, A. Vlaar, M. Bauer, D. Annane +28 more
2023D16. ADVANCING THE SCIENCE OF ARDS AND ACUTE RESPIRATORY FAILURE2 citations
Semantic Scholar
Inhibiting C5 in patients with severe COVID-19—the incorrect target?
E. H. T. Lim, A. Vlaar, M. Brouwer, D. van de Beek
2023The Lancet Respiratory Medicine2 citations Open access
Semantic Scholar
Inflammatory biomarkers at hospital discharge are associated with readmission and death in patients hospitalized for COVID-19
M. A. Slim, B. Appelman, Marcella C. A. Müller, M. Brouwer +3 more
2021European Journal of Clinical Microbiology and Infectious Diseases2 citations Open access
Semantic Scholar
Efficacy matters: broadening complement inhibition in COVID-19 – Authors' reply
A. Vlaar, S. de Bruin, M. Brouwer, D. van de Beek
2020The Lancet Rheumatology2 citations Open access
Semantic Scholar
Hemolysis and Acute Kidney Injury Following Cardiac Surgery With Cardiopulmonary Bypass in Patients With Preexisting Renal Dysfunction.
C. Volleman, P. Phelp, Dionne P C Dubelaar, A. T. Tuip-de Boer +4 more
2026Journal of Cardiothoracic and Vascular Anesthesia1 citations Open access
Semantic Scholar
Biomarker analysis provides evidence for host response homogeneity in patients with COVID-19
R. V. van Amstel, Erik H. A. Michels, B. Appelman, J. de Brabander +81 more
2024CHEST Critical Care1 citations Open access
Semantic Scholar
Targeting C5a is beneficial in critically ill COVID-19 patients.
E. H. T. Lim, A. Vlaar, M. Brouwer, D. van de Beek
2023Immunobiology1 citations Open access
Semantic Scholar
C5a-C5aR1 Axis Blockade in Patients With Severe COVID-19: Differences Between PANAMO and FORCE Study.
E. H. T. Lim, A. Vlaar, M. Brouwer, D. van de Beek
2023Critical Care Medicine1 citations
Semantic Scholar
Pulmonary herpesvirus reactivation in patients with persistent acute respiratory failure: a single-centre prospective observational cohort study
A. Harbiye, Shi-Qi Zhang, L. Kramer, H. B. van den Heuvel +47 more
2026Critical Care0 citations Open access
Semantic Scholar
Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients
E. Lim, D. van de Beek, S. de Bruin, S. Rückinger +8 more
2025BMJ Open Respiratory Research0 citations Open access
Semantic Scholar
Vilobelimab in Combination with Tocilizumab, Levilimab or Baricitinib Improves Mortality in COVID-19 ARDS Patients: A Post-hoc Subgroup Analysis of the PANAMO Phase III Study
A. F. Shorr, A. Vlaar, E.H.T. Lim, R. Chemaly +7 more
2025CHEST Critical Care0 citations Open access
Semantic Scholar
Dynamic Transitions of the Hyperinflammatory and Hypoinflammatory Subphenotypes in Critical Illness: Implications for Clinical Outcomes
R. V. van Amstel, B. Bartek, A. Vlaar, E. Gay +7 more
2024C96. PRECISION MEDICINE IN CRITICAL CARE: EXPLORING ARDS AND SEPSIS PHENOTYPES0 citations
Semantic Scholar
87. The safety and efficacy advantage of blocking C5a vs C5 in critically ill, COVID-19 patients: Results from PANAMO, a Phase 3 randomized controlled trial
B. Burnett, E. Lim, A. Vlaar, S. de Bruin +10 more
2023Open Forum Infectious Diseases0 citations Open access
Semantic Scholar
C5 inhibitors are not C5a inhibitors
E. H. T. Lim, A. Vlaar, S. de Bruin, M. Brouwer +1 more
2023Expert Review of Anti-Infective Therapy0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. van de Beek×26
Invite
D. van de Beek — researcher profile on SciRah
M. Brouwer×22
Invite
M. Brouwer — researcher profile on SciRah
T. van der Poll×21
Invite
T. van der Poll — researcher profile on SciRah
L. V. van Vught×18
Invite
L. V. van Vught — researcher profile on SciRah

×16

Invite

L. Heunks — researcher profile on SciRah

S. de Bruin×16

Invite

S. de Bruin — researcher profile on SciRah

Invite

M. A. Slim — researcher profile on SciRah

Invite

L. Bos — researcher profile on SciRah

J. de Brabander×14

Invite

J. de Brabander — researcher profile on SciRah

Invite

E. Nossent — researcher profile on SciRah

E. H. T. Lim×12

Invite

E. H. T. Lim — researcher profile on SciRah

W. Wiersinga×11

Invite

W. Wiersinga — researcher profile on SciRah